Recent advances have focused on improving vector design and delivery methods. Researchers are developing vectors with enhanced targeting capabilities, such as those that exploit cancer-specific biomarkers for precise delivery. Additionally, the use of CRISPR-Cas9 gene-editing technology has opened new avenues for correcting genetic mutations directly within cancer cells. Nanotechnology is also playing a pivotal role by enabling the design of nanoparticles that can deliver genes and therapeutic agents simultaneously.
